|Vical enters into agreement to manufacture HIV vaccine|
|By Staff and Wire Reports|
|Thursday, 07 October 2010 07:56|
Vical Incorporated (NASDAQ:VICL) announced today that it has received a contract of $2.4 million from IPPOX foundation to manufacture Plasmid DNA (pDNA) vaccines for the treatment of HIV.
Developed by EuroVacc program in 1998, a pDNA/Poxvirus boost program is currently in focus of the ‘Collaboration for AIDS Vaccine Discovery’s (CAVD)’ Poxvirus T-cell vaccine discovery consortium. Multiple Phase-1 and 2 Clinical trials in Europe of the DNA/Poxvirus approach has been proven to be highly immunogenic. Further clinical developments can be carried out in Africa if the results of human studies prove successful.